Advertisement
AXON vs INSM
Which Stock Would AI Choose? Axon Enterprise (AXON) vs. Insmed (INSM) Stock Comparison
Key Takeaways
- Axon Enterprise (AXON), a leader in public safety technology, boasts a market capitalization of approximately $32 billion and year-to-date (YTD) gains of 29%, though shares have pulled back in recent market activity.
- Insmed (INSM), a biopharmaceutical firm focused on rare diseases, has a similar $29 billion market cap and YTD return of 23%, supported by pipeline advancements.
- AXON benefits from recurring software and services revenue, contrasting with INSM's reliance on clinical trial outcomes and drug approvals.
- Recent weeks show AXON introducing AI-enhanced products amid a monthly dip, while INSM anticipates first-quarter earnings and investor conferences.
- Both stocks exhibit high growth potential but diverge in risk profiles, with INSM facing greater biotech volatility.
Introduction
This stock comparison between Axon Enterprise (AXON) and Insmed (INSM) highlights two high-growth names in distinct sectors: public safety technology and biopharmaceuticals. Traders seeking momentum plays and investors eyeing long-term catalysts may find value in evaluating their relative performance, valuations, and market positioning. Amid recent market volatility, AXON's AI integrations contrast with INSM's clinical pipeline progress. This analysis draws on current financial metrics and sentiment shifts to aid informed decision-making in today's dynamic environment.
AXON Overview and Recent Performance
Axon Enterprise (AXON) develops public safety solutions, including conducted energy devices like TASERs, body cameras, and cloud-based software-as-a-service (SaaS) platforms for evidence management. The company reported strong quarterly revenue growth, driven by software and services expansion, with shares trading around $402 and a price-to-earnings (PE) ratio of 263. In recent weeks, the stock has experienced a pullback of about 7% over the past month, influenced by broader market concerns over debt levels and valuation amid a 52-week range of $339 to $886. Positive sentiment stems from AI innovations like Axon 911 and expanded assistant tools, reinforcing its moat in the public safety sector, though investors weigh growth sustainability against high multiples.
INSM Overview and Recent Performance
Insmed (INSM) focuses on therapies for rare pulmonary diseases, with approved product ARIKAYCE for nontuberculous mycobacterial lung infections and brensocatib in phase 3 for bronchiectasis. Shares hover near $133, with no PE ratio due to ongoing losses, and a market cap of $29 billion within a 52-week range of $64 to $213. Recent market activity shows stability, buoyed by upcoming first-quarter earnings on May 7 and investor conferences, alongside analyst upgrades to price targets around $230. Sentiment reflects optimism for pipeline catalysts like the ENCORE study, tempered by clinical risks and prior trial setbacks, positioning INSM as a high-reward biotech contender.
Trending AI Robots
Tickeron’s Trending AI Robots page features a curated selection of the platform’s top-performing AI trading bots, drawn from a library of 351 bots that trade thousands of tickers across stocks, ETFs, and crypto. These bots employ machine learning for technical and fundamental analysis, showcasing diverse strategies—from short-term scalping (e.g., 5-60 minutes) to swing trading—with impressive stats like annualized returns up to +163%, win rates reaching 88%, and profit factors as high as 7. Only the most suitable for current conditions, such as volatility in semiconductors or industrials, earn a spot among the 25 trending agents. Explore these high-performing bots to align with prevailing market themes and enhance your trading edge.
Head-to-Head Comparison
Axon Enterprise (AXON) and Insmed (INSM) represent contrasting business models: AXON's hardware-SaaS hybrid yields recurring revenue from government contracts, while INSM depends on drug commercialization and trial successes. Growth drivers differ—AXON leverages AI in public safety amid rising demand, versus INSM's rare disease focus with potential blockbusters. Recent momentum favors AXON's YTD edge, but INSM shows resilience. Risk factors include AXON's elevated valuation and debt, against INSM's binary clinical outcomes. Sector exposure pits industrials stability against healthcare volatility, with market sentiment tilting toward AXON's consistency.
Tickeron AI Verdict
Tickeron’s AI models currently favor AXON over INSM, citing superior trend consistency, recurring revenue stability, and AI-driven catalysts in recent market activity. While INSM offers upside from pipeline milestones, its higher volatility introduces greater uncertainty compared to AXON's established positioning.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AXON is a Buy and INSM is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AXON’s FA Score shows that 0 FA rating(s) are green whileINSM’s FA Score has 0 green FA rating(s).
- AXON’s FA Score: 0 green, 5 red.
- INSM’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AXON’s TA Score shows that 6 TA indicator(s) are bullish while INSM’s TA Score has 4 bullish TA indicator(s).
- AXON’s TA Score: 6 bullish, 2 bearish.
- INSM’s TA Score: 4 bullish, 6 bearish.
Price Growth
AXON (@Aerospace & Defense) experienced а -0.34% price change this week, while INSM (@Biotechnology) price change was -7.41% for the same time period.
The average weekly price growth across all stocks in the @Aerospace & Defense industry was -1.86%. For the same industry, the average monthly price growth was -4.27%, and the average quarterly price growth was +54.11%.
The average weekly price growth across all stocks in the @Biotechnology industry was -4.47%. For the same industry, the average monthly price growth was -8.01%, and the average quarterly price growth was +5.85%.
Reported Earning Dates
AXON is expected to report earnings on Aug 11, 2026.
INSM is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Aerospace & Defense (-1.86% weekly)Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.
@Biotechnology (-4.47% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| AXON | INSM | AXON / INSM | |
| Capitalization | 31.6B | 23.3B | 136% |
| EBITDA | 320M | -1.08B | -30% |
| Gain YTD | -30.918 | -38.284 | 81% |
| P/E Ratio | 158.20 | N/A | - |
| Revenue | 2.98B | 820M | 364% |
| Total Cash | 737M | 1.22B | 60% |
| Total Debt | 1.83B | 580M | 315% |
AXON | INSM | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 73 | 7 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 83 Overvalued | 72 Overvalued | |
PROFIT vs RISK RATING 1..100 | 71 | 61 | |
SMR RATING 1..100 | 80 | 100 | |
PRICE GROWTH RATING 1..100 | 64 | 65 | |
P/E GROWTH RATING 1..100 | 61 | 100 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
INSM's Valuation (72) in the Biotechnology industry is in the same range as AXON (83). This means that INSM’s stock grew similarly to AXON’s over the last 12 months.
INSM's Profit vs Risk Rating (61) in the Biotechnology industry is in the same range as AXON (71). This means that INSM’s stock grew similarly to AXON’s over the last 12 months.
AXON's SMR Rating (80) in the Biotechnology industry is in the same range as INSM (100). This means that AXON’s stock grew similarly to INSM’s over the last 12 months.
AXON's Price Growth Rating (64) in the Biotechnology industry is in the same range as INSM (65). This means that AXON’s stock grew similarly to INSM’s over the last 12 months.
AXON's P/E Growth Rating (61) in the Biotechnology industry is somewhat better than the same rating for INSM (100). This means that AXON’s stock grew somewhat faster than INSM’s over the last 12 months.
| AXON | INSM | |
|---|---|---|
| RSI ODDS (%) | 7 days ago 81% | 1 day ago 84% |
| Stochastic ODDS (%) | 1 day ago 81% | 1 day ago 78% |
| Momentum ODDS (%) | 1 day ago 78% | 6 days ago 84% |
| MACD ODDS (%) | 3 days ago 77% | 7 days ago 75% |
| TrendWeek ODDS (%) | 1 day ago 67% | 1 day ago 72% |
| TrendMonth ODDS (%) | 1 day ago 70% | 1 day ago 78% |
| Advances ODDS (%) | 3 days ago 74% | 8 days ago 71% |
| Declines ODDS (%) | 8 days ago 69% | 3 days ago 73% |
| BollingerBands ODDS (%) | 1 day ago 62% | 1 day ago 88% |
| Aroon ODDS (%) | 1 day ago 73% | 1 day ago 80% |
Advertisement
INSM and
Correlation & Price change
A.I.dvisor indicates that over the last year, INSM has been closely correlated with CNTN. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if INSM jumps, then CNTN could also see price increases.
| Ticker / NAME | Correlation To INSM | 1D Price Change % | ||
|---|---|---|---|---|
| INSM | 100% | +0.24% | ||
| CNTN - INSM | 74% Closely correlated | +0.31% | ||
| TRDA - INSM | 44% Loosely correlated | -4.24% | ||
| ENGN - INSM | 42% Loosely correlated | -2.04% | ||
| AXON - INSM | 40% Loosely correlated | -1.76% | ||
| ARRY - INSM | 40% Loosely correlated | -4.62% | ||
More | ||||